Drug intelligence / Profile preview

ibrutinib + arsenic trioxide

Development stage: Unknown
Lead developer: Pharmacyclics
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

A combination therapy consisting of ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, and arsenic trioxide, an antineoplastic agent. Ibrutinib works by irreversibly inhibiting BTK, which is important in B-cell development and signaling. Arsenic trioxide works through multiple mechanisms including promoting degradation of the PML-RARA oncoprotein in acute promyelocytic leukemia. This combination has been investigated for the treatment of chronic lymphocytic leukemia (CLL).

Other names: Ibrutinib + As2O3

Targets

PML-RARA (PML-retinoic acid receptor alpha fusion protein)CSRP (Cysteine and glycine-rich protein)BTK (Bruton tyrosine kinase)ITK (Interleukin 2-inducible T-cell kinase)

Beyond the preview

Go deeper on ibrutinib + arsenic trioxide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ibrutinib + arsenic trioxide.

Explore the full profile